5270-94-0

Basic information

• Product Name: 4,6-Dimethoxypyrimidine
• Synonyms: 4,6-DIMETHOXYPYRIMIDINE;4,6-dimethyloxypyrimidine;Pyrimidine, 4,6-dimethoxy- (6CI,7CI,8CI,9CI);4,6-Dimethoxypyrimdine
• CAS NO: 5270-94-0
• Molecular Formula: C₆H₈N₂O₂
• Molecular Weight: 140.14
• Product Categories: PYRIMIDINE;APIs & Intermediate
• Mol File: 5270-94-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 33 °C
• Boiling Point: 186 °C
• Flash Point: 87 °C
• Appearance: Colorless to pale-yellow liquid
• Density: 1.131 g/cm³
• Vapor Pressure: 0.0648mmHg at 25°C
• Refractive Index: 1.489
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 1.48±0.17(Predicted)
• CAS DataBase Reference: 4,6-Dimethoxypyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dimethoxypyrimidine(5270-94-0)
• EPA Substance Registry System: 4,6-Dimethoxypyrimidine(5270-94-0)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 5270-94-0(Hazardous Substances Data)

Usage

Chemical Properties

Yellow liquid

InChI:InChI=1/C6H8N2O2/c1-9-5-3-6(10-2)8-4-7-5/h3-4H,1-2H3

Upstream product

• 13223-25-1 2-chloro-4,6-dimethoxypyrimidine 
• 75-09-2 dichloromethane 
• 584-08-7 potassium carbonate 
• 2258-42-6 formyl acetic anhydride 
• 1193-21-1 4,6-dichloropyrimidine 
• 124-41-4 sodium methylate 

Downstream Products

• 126327-70-6 (4,6-Dimethoxy-pyrimidin-5-yl)-phenyl-methanol 
• 126327-71-7 (4,6-Dimethoxy-pyrimidin-5-yl)-phenyl-methanone 
• 13566-63-7 5-Methyl-4,6-dimethoxy-pyrimidin 
• 4319-77-1 5-bromo-4,6-dimethoxypyrimidine 
• 491871-36-4 4-[(4,6-dimethoxypyrimidin-2-yl)oxy]benzaldehyde 

Relevant articles and documents

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Process for the production of 4,6-dialkoxypyrimidines

A process for the production of 4,6-dialkoxypyrimidines of the general formula: STR1 A propanediimidate of the general formula: STR2 is converted with an anhydride of the general formula: STR3 to provide the product.